Based upon the FDA approval and noted reference, the panel consensus was to include duvelisib as a relapsed/refractory therapy option with a category 2A recommendation for:

- **CLL/SLL without del(17p)/TP53 mutation**
  - Frail patient with significant comorbidity or age ≥65 y and younger patients with significant comorbidities
  - Age <65 y without significant comorbidities
- **CLL/SLL with del(17p)/TP53 mutation**
